← Leaderboards
Balamurali K Ambati
Augusta University
$10,199,905
Attributed
$10,304,905
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2007–21$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$10,304,905 · 4
VA$0 · 2
By mechanism
R01$10,164,905 · 3
R43$140,000 · 1
I01$0 · 1
I21$0 · 1
Top collaborators
- Thomas Preston Kennedy1 shared
- Glenn D Prestwich1 shared
- Jianxing Zhang1 shared
Others in their field
Top investigators on “Corneal Neovascularization”
- Keri Hammel · The Emmes Company, Llc$11,951,805
- Keri, Hammel · The Emmes Company, Llc$11,064,901
- Rajiv Ravindra Mohan · University Of Missouri-Columbia$8,475,366
- Rajesh Agarwal · University Of Colorado Denver$6,752,357
- Dimitri T. Azar · Schepens Eye Research Institute$6,497,862
- Reza Dana · Schepens Eye Research Institute$6,269,672
Research focus
Corneal NeovascularizationCorneaBlood VesselsAngiogenesisVisionMolecularSignal TransductionTraumaVascular Endothelial Growth Factor Receptor-1Macular DegenerationStructureBaseVascular Endothelial Growth FactorsKeratoplastyCellsLasersReceptorVisualChoroidal NeovascularizationOcular AngiogenesisEventMediator Of Activation ProteinExtracellularVascular Endothelial Growth Factor Receptor
Grant awards (43)
NEUROVASCULAR CROSS-TALK, FUNCTIONS AND SOURCES OF SOLUBLE VEGF RECEPTORS IN OCULAR VASCULAR DEMARCATION$357,688
R01 · FY2021 · EY · contact PI
Neurovascular Cross-Talk, Functions and Sources of Soluble VEGF Receptors in Ocular Vascular Demarcation$330,393
R01 · FY2020 · EY · contact PI
NEUROVASCULAR CROSS-TALK, FUNCTIONS AND SOURCES OF SOLUBLE VEGF RECEPTORS IN OCULAR VASCULAR DEMARCATION$61,707
R01 · FY2020 · EY · contact PI
NEUROVASCULAR CROSS-TALK, FUNCTIONS AND SOURCES OF SOLUBLE VEGF RECEPTORS IN OCULAR VASCULAR DEMARCATION$273,899
R01 · FY2019 · EY · contact PI
COMP-Ang1: Vascular Normalization and Neuroprotection for Diabetic Retinopathy$185,053
R01 · FY2019 · EY · contact PI
COMP-ANG1: VASCULAR NORMALIZATION AND NEUROPROTECTION FOR DIABETIC RETINOPATHY$150,196
R01 · FY2019 · EY · contact PI
Neurovascular cross-talk, functions and sources of soluble VEGF receptors in ocular vascular demarcation$107,351
R01 · FY2019 · EY · contact PI
Neurovascular cross-talk, functions and sources of soluble VEGF receptors in ocular vascular demarcation$380,626
R01 · FY2018 · EY · contact PI
COMP-Ang1: Vascular Normalization and Neuroprotection for Diabetic Retinopathy$335,250
R01 · FY2018 · EY · contact PI
Intraceptor Interference of VEGF in Ocular Angiogenesis$372,606
R01 · FY2017 · EY · contact PI
COMP-Ang1: Vascular Normalization and Neuroprotection for Diabetic Retinopathy$335,250
R01 · FY2017 · EY · contact PI
Intraceptor Interference of VEGF in Ocular Angiogenesis$372,606
R01 · FY2016 · EY · contact PI
The Role of Soluble Flt-1 and Raver2 in Ocular Vascular Demarcations$372,500
R01 · FY2016 · EY · contact PI
COMP-Ang1: Vascular Normalization and Neuroprotection for Diabetic Retinopathy$335,250
R01 · FY2016 · EY · contact PI
Synergistic OEC-biologic Use for Diabetic Retinal Regeneration$0
I21 · FY2016 · VA · contact PI
Intraceptor Interference of VEGF in Ocular Angiogenesis$365,153
R01 · FY2015 · EY · contact PI
The Role of Soluble Flt-1 and Raver2 in Ocular Vascular Demarcations$365,050
R01 · FY2015 · EY · contact PI
Intraceptor Interference of VEGF in Ocular Angiogenesis$97,000
R01 · FY2015 · EY · contact PI
Targeted Morpholino Interference of VEGF Pathways in Ocular Angiogenesis$0
I01 · FY2015 · VA · contact PI
Synergistic OEC-biologic Use for Diabetic Retinal Regeneration$0
I21 · FY2015 · VA · contact PI
Intraceptor Interference of VEGF in Ocular Angiogenesis$392,028
R01 · FY2014 · EY · contact PI
The Role of Soluble Flt-1 and Raver2 in Ocular Vascular Demarcations$365,050
R01 · FY2014 · EY · contact PI
The Role of Soluble Flt-1 and Raver2 in Ocular Vascular Demarcations$94,000
R01 · FY2014 · EY · contact PI
Targeted Morpholino Interference of VEGF Pathways in Ocular Angiogenesis$0
I01 · FY2014 · VA · contact PI
The Role of Soluble Flt-1 and Raver2 in Ocular Vascular Demarcations$372,500
R01 · FY2013 · EY · contact PI
Pre-mRNA Interference of VEGF Pathways in Ocular Angiogenesis$0
I01 · FY2013 · VA · contact PI
The Role of sFlt in Corneal Avascularity$321,829
R01 · FY2012 · EY · contact PI
Pre-mRNA Interference of VEGF Pathways in Ocular Angiogenesis$0
I01 · FY2012 · VA · contact PI
Intraceptor Interference of VEGF Pathways$465,228
R01 · FY2011 · EY · contact PI
The Role of sFlt in Corneal Avascularity$321,829
R01 · FY2011 · EY · contact PI
The Role of sFlt in Corneal Avascularity$99,406
R01 · FY2011 · EY · contact PI
Pre-mRNA Interference of VEGF Pathways in Ocular Angiogenesis$0
I01 · FY2011 · VA · contact PI
Intraceptor Interference of VEGF Pathways$371,622
R01 · FY2010 · EY · contact PI
The Role of sFlt in Corneal Avascularity$335,239
R01 · FY2010 · EY · contact PI
Intraceptor Interference of VEGF Pathways$112,875
R01 · FY2010 · EY · contact PI
Intraceptor Interference of VEGF Pathways$375,375
R01 · FY2009 · EY · contact PI
The Role of sFlt in Corneal Avascularity$338,625
R01 · FY2009 · EY · contact PI
The Role of sFlt in Corneal Avascularity$338,625
R01 · FY2009 · EY · contact PI
Sulfated Polysaccharide Derivatives for Treatment of Macular Degeneration$140,000
R43 · FY2009 · EY
Pre-mRNA Interference of VEGF Pathways in Ocular Angiogenesis$0
I01 · FY2009 · VA · contact PI
Intraceptor Interference of VEGF Pathways$367,500
R01 · FY2008 · EY · contact PI
The Role of sFlt in Corneal Avascularity$338,251
R01 · FY2008 · EY · contact PI
Intraceptor Interference of VEGF Pathways$357,345
R01 · FY2007 · EY · contact PI